Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | APLNR | P35414 | 1/20 | 0.55 |
| ▸ | GLP1R | P43220 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | RORC | P51449 | 6/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2863389 | 0.94 | NPSR1 (0.56) | NPSR1GPR119ADRB2APLNRGLP1R | |
| SCHEMBL2861921 | 0.94 | NPSR1 (0.53) | NPSR1GPR119ADRB2APLNRGLP1R | |
| SCHEMBL2861988 | 0.90 | NPSR1 (0.52) | NPSR1GPR119ADRB2APLNRGLP1R | |
| SCHEMBL2868953 | 0.88 | NPSR1 (0.57) | NPSR1GPR119ADRB2APLNRGLP1R | |
| SCHEMBL2869200 | 0.88 | NPSR1 (0.52) | NPSR1GPR119ADRB2APLNRGLP1R | |
| SCHEMBL2856780 | 0.85 | NPSR1 (0.43) | NPSR1GPR119ADRB2APLNRGLP1R | |
| SCHEMBL2860641 | 0.84 | NPSR1 (0.62) | NPSR1GPR119ADRB2APLNRGLP1R | |
| SCHEMBL2864501 | 0.82 | NPSR1 (0.57) | NPSR1GPR119ADRB2APLNRGLP1R | |
| SCHEMBL2870570 | 0.82 | NPSR1 (0.57) | NPSR1GPR119ADRB2APLNRGLP1R | |
| SCHEMBL2865918 | 0.82 | NPSR1 (0.47) | NPSR1GPR119ADRB2APLNRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | NPSR1 211/4885GPR119 75/4885ADRB2 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.